期刊文献+

活性维生素D_3与足细胞 被引量:3

下载PDF
导出
摘要 近年来研究发现活性维生素D3具有独立于钙磷代谢之外的肾脏保护作用,足细胞是其重要的作用靶点之一。本文从足细胞生物学特征、活性维生素D3的生物学特点与维生素D受体相互作用的机制,及其对足细胞作用与可能机制进行阐述;同时展望活性维生素D3及其类似物的应用前景。
作者 马建超 史伟
出处 《广东医学》 CAS CSCD 北大核心 2011年第3期384-386,共3页 Guangdong Medical Journal
基金 广东省医学科学基金资助项目(编号:A2010007)
  • 相关文献

参考文献6

  • 1SHANKLAND S J.The podocyte′s response to injury:role in proteinuria and glomerulosclerosis[J].Kidney Int,2006,69(12):2131-2147.
  • 2LI Y,SPATARO B C,YANG J,et al.1,25-Dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression[J].Kidney Int,2005,68(4):1500-1510.
  • 3SZETO C C,CHOW K M,KWAN B C,et al.Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy:an uncontrolled trial[J].Am J Kidney Dis,2008,51(5):724-731.
  • 4XIAO H Q,SHI W,LIU S,et al.1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway[J].Am J Nephrol,2009,30(1):34-43.
  • 5BOUILLON R,OKAMURA W H,NORMAN A W.Structure-function relationship in the vitamin D endocrine system[J].Endocr Rev,1995,16(2):250-257.
  • 6SAMUEL S,SITRIN M D.Vitamin D′s role in cell proliferation and differentiation[J].Nutr Rev,2008,66(10 Suppl 2):S116-S124.

同被引文献60

  • 1李月红,黄海长,章友康,王素霞,邹万忠.局灶节段性肾小球硬化症大鼠尿足细胞动态检测及其意义[J].中华肾脏病杂志,2005,21(2):98-102. 被引量:20
  • 2李惊子,黄海长,刘颖,鄂杰.检测尿足细胞在活动性肾小球疾病中的意义[J].北京大学学报(医学版),2005,37(5):463-466. 被引量:34
  • 3<活性维生素D的合理应用>专家协作组.活性维生素D在慢性肾脏病继发性甲旁亢中合理应用的专家共识(修订版)[J].中华肾脏病杂志,2005,21(11):698-699. 被引量:97
  • 4邢国兰,胡晓舟,刘章锁,李中琳.慢性肾脏病治疗的临床决策[J].医学与哲学(B),2007,28(9):42-43. 被引量:4
  • 5PETERMANN A,FLOEGE J. Podocyte damage resulting in podo-cyturia : a potential diagnostic marker to assess glomerular diseaseactivity[ J]. Nephron Clin Pract,2007, 106(2) : 61 -66.
  • 6Levey A S, Cattran D, Friedman A, et al. Proteinuria as a surro gate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Admin- istration[J].Am J Kidney Dis, 2009,54(2) :205-226.
  • 7Moe S M, Drueke T. Improving global outcomes in mineral and bone disorders[J]. Clin J Am Soc Nephrol, 2008,3 ( Suppl 3) :S127-S130.
  • 8Fishbane S, Chiuineni H, Packman M, et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trail [J]. Am J Kidney Dis,2009,54(4) :647-652.
  • 9de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin I) re ceptor activation with paricaleitol for reduction of albuminuria in pa tients with type 2 diabetes (VITAL study): a randomised con- trolled trial[J]. I.ancet,2010,376(9752) :1543-1551.
  • 10Zhang Z, Sun L, Wang Y, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy[J].Kidney Int, 2008,73 ( 2 ) : 163-171.

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部